Hilbert Michelle, Kuzman Peter, Mueller Wolf C, Nestler Ulf
Department of Neurosurgery, University Hospital Leipzig, 04103 Leipzig, Germany.
Paul-Flechsig-Institute of Neuropathology, University Hospital Leipzig, 04103 Leipzig, Germany.
Biology (Basel). 2022 Jul 7;11(7):1021. doi: 10.3390/biology11071021.
Serum levels of apolipoprotein ApoC1 have been described in a number of systemic tumor entities as potential biomarkers, but little is known about ApoC1 in neurosurgical patients. A total of 230 serum samples from 96 patients were analyzed using an ELISA technique. Patient diagnoses comprised 70 glioblastomas WHO IV°, 10 anaplastic astrocytomas III°, one anaplastic oligodendroglioma III°, one oligodendroglioma II°, one diffuse astrocytoma II°, one pilocytic astrocytoma I°, and a single case of a spindle cell tumor without WHO grading, as well as 11 spinal interventions. The mean ApoC1 level of the 230 samples was 132.03 µg/mL (median 86.83, SD 292.91). In the 176 glioblastoma samples, the mean ApoC1 level was 130.0 µg/mL (median 86.23, SD 314.9), which was neither different from the whole group nor from patients with spinal interventions (215.1 μg/mL, median 63.6, SD 404.9). In the postoperative samples, the mean ApoC1 level was significantly lower (85.81 μg/mL) than in the preoperative samples (129.64 μg/mL) and in samples obtained during adjuvant chemotherapy (168.44 μg/mL). While absolute ApoC1 serum levels in a patient do not allow for the distinction between neurosurgical histological entities, future analyses will examine whether the time course of ApoC1 in an individual patient can be related to certain treatment stages.
血清载脂蛋白ApoC1水平在许多全身性肿瘤实体中已被描述为潜在的生物标志物，但对于神经外科患者的ApoC1却知之甚少。使用酶联免疫吸附测定（ELISA）技术对96例患者的230份血清样本进行了分析。患者诊断包括70例世界卫生组织（WHO）IV级胶质母细胞瘤、10例III级间变性星形细胞瘤、1例III级间变性少突胶质细胞瘤、1例II级少突胶质细胞瘤、1例II级弥漫性星形细胞瘤、1例I级毛细胞型星形细胞瘤，以及1例未进行WHO分级的梭形细胞瘤病例，还有11例脊柱手术病例。230份样本的平均ApoC1水平为132.03μg/mL（中位数86.83，标准差292.91）。在176份胶质母细胞瘤样本中，平均ApoC1水平为130.0μg/mL（中位数86.23，标准差314.9），这与整个组以及脊柱手术患者（215.1μg/mL，中位数63.6，标准差404.9）均无差异。术后样本中的平均ApoC1水平（85.81μg/mL）显著低于术前样本（129.64μg/mL）和辅助化疗期间获得的样本（168.44μg/mL）。虽然患者的ApoC1血清绝对水平无法区分神经外科组织学实体，但未来的分析将研究个体患者中ApoC1的时间进程是否与某些治疗阶段相关。
